Repligen Corporation (US-Massachusetts) Drug Class: Small molecule Mechanism/Technology: Developing Uridine as a therapy for bipolar disorder. Uridine is a biological compound essential for the synthesis of DNA, RNA and numerous other factors essential for cell metabolism. Uridine is synthesized by mitochondria. Research indicates that mitochondrial dysfunction is involved in bipolar disorder, which suggests that uridine may be useful in this disease. Developing HDAC inhibitors for Friedrich's Ataxia and Huntington's and currently evaluating in preclinical models Primary Indication: Bipolar Disorder, Friedrich's Ataxia, Huntington's Disease Stage: Preclinical
